Methylene Blue Antimicrobial and Antiviral Properties: A Research Overview

Methylene blue (MB), a synthetic phenothiazine dye with over a century of pharmaceutical history, has drawn growing scientific interest for its antimicrobial and antiviral properties. At the core of this interest is MB’s function as a photosensitizer: when activated by light of an appropriate wavelength, it generates reactive oxygen species (ROS) capable of damaging pathogens. This mechanism — antimicrobial photodynamic therapy, or aPDT — has been investigated against drug-resistant bacteria, persistent biofilms, and, more recently, viruses including SARS-CoV-2.

This article summarizes peer-reviewed findings on MB’s antimicrobial and antiviral activity. The overwhelming majority of evidence comes from in vitro laboratory studies, and clinical translation remains early-stage. What follows is a research overview, not a guide to self-treatment. Readers with health conditions or questions about therapeutic use should consult a qualified physician.

How Antimicrobial Photodynamic Therapy Works

Antimicrobial photodynamic therapy relies on three components working together: a photosensitizer, light of an appropriate wavelength, and molecular oxygen. Methylene blue absorbs red and near-infrared light, and in that excited state it transfers energy to nearby oxygen molecules, producing singlet oxygen and other reactive species. These ROS attack microbial membranes, cell walls, proteins, and nucleic acids with relatively broad-spectrum damage, making it difficult for pathogens to develop targeted resistance through single mutations.

Despite this mechanistic logic, research has shown that activating the photosensitizer is only one piece of the puzzle. A 2023 study ^[10] emphasized that photosensitizer excitation alone is frequently insufficient for meaningful clinical outcomes — delivery to the target site, adequate local concentration, light dose, and the specific physical properties of the microbial target all critically influence whether photodynamic inactivation succeeds or falls short. This caveat is important context for interpreting positive in vitro findings.

Activity Against Drug-Resistant Bacterial Biofilms

Biofilms — communities of bacteria encased in a self-produced matrix — are significantly harder to kill than free-floating (planktonic) bacteria, partly because the matrix physically limits photosensitizer penetration. Research has tested MB-based aPDT against some of the most clinically problematic biofilm-forming organisms. A 2020 in vitro study ^[3] examined MB-mediated photodynamic inactivation of multidrug-resistant Acinetobacter baumannii biofilms, a pathogen of major concern in hospital-acquired infections. The study used Protoporphyrin IX alongside MB and found significant reductions in biofilm viability under appropriate light activation.

Dental biofilms have also been a focus of investigation. A 2020 study ^[4] compared MB and chlorin e6 as photosensitizers against Streptococcus mutans biofilms, a primary driver of dental caries. Both photosensitizers reduced biofilm viability in vitro, though outcomes depended on photosensitizer concentration and light parameters. These findings situate MB aPDT as a potential adjunct in oral antimicrobial applications, though the step from laboratory dish to clinical dentistry requires substantially more evidence.

Editor’s Pick

Methylene Blue Gummies, 7mg of Methylene Blue，99.9% Pure, Per Gummy for Sustained Energy,L

Gummies

Get Best Price › As an Amazon Associate we earn from qualifying purchases.

Combination Strategies: Improving Photodynamic Efficacy

Because biofilm matrix and microbial resistance mechanisms limit aPDT’s reach, researchers have explored combination approaches. Potassium iodide (KI) has emerged as a useful adjunct: when singlet oxygen reacts with KI, it generates secondary reactive species including iodine radicals, broadening the oxidative attack. A 2022 study ^[7] found that KI enhanced red-laser aPDT inactivation of S. mutans biofilm, suggesting that combining MB with KI amplifies the photodynamic kill compared with either component alone.

A different limitation is posed by bacterial efflux pumps — membrane proteins that actively expel photosensitizers from inside the cell, reducing effective intracellular concentration. A 2010 study ^[1] demonstrated that adding an efflux pump inhibitor potentiated MB-based aPDT against Enterococcus faecalis biofilm, pointing to efflux as a meaningful resistance mechanism worth addressing in protocol design.

Nano-scale delivery is another active area. A 2019 study ^[2] conjugated MB to carbon nanotubes and tested the resulting construct against E. coli and S. aureus, finding photodynamic antimicrobial effects. The rationale is that nanotubes may improve photosensitizer accumulation at the microbial surface. While intriguing, nanoparticle delivery adds its own safety and regulatory complexity that is far from resolved for clinical use.

Antiviral Activity: SARS-CoV-2 Laboratory Findings

Interest in MB as an antiviral spiked during the COVID-19 pandemic. A 2021 in vitro study ^[5] demonstrated photodynamic inactivation of SARS-CoV-2 using both MB and Radachlorin, suggesting that light-activated MB can disrupt viral particles outside of cells. Around the same time, mechanistic investigations began examining how MB might interfere with viral entry. A 2020 study ^[6] proposed that MB inhibits the binding interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor — a critical step through which the virus gains entry into host cells — offering a photodynamic-independent mechanism of potential antiviral action.

A 2022 study ^[8] took a broader view, characterizing MB as a nonspecific protein-protein interaction (PPI) inhibitor. The hypothesis is that MB’s planar aromatic structure allows it to intercalate at protein interfaces, disrupting multiple binding events that viruses depend on for replication and entry. While this breadth of action is mechanistically interesting, nonspecificity is a double-edged property — it raises questions about off-target effects on host protein interactions at antiviral concentrations.

Molecular Modeling and Computational Approaches

Computational chemistry has provided additional hypothesis-generating data. A 2023 molecular modeling study ^[11] examined the interaction of MB with the SARS-CoV-2 envelope protein, identifying plausible binding geometries and energetically favorable poses. The envelope protein plays roles in viral assembly and budding, making it a potential therapeutic target. Separately, a 2023 study ^[9] applied both computational and experimental methods to examine antimalarial compounds — a relevant comparison class, since MB itself has a long history in malaria — against the papain-like protease of SARS-CoV-2.

These in silico findings are useful for generating testable hypotheses and prioritizing compounds for experimental follow-up, but they are not evidence of clinical efficacy. Predicted binding in a computational model does not confirm that the same interaction occurs in living cells, and it does not account for drug metabolism, distribution, or competing protein binding in a biological system.

A Critical Caveat: The Extracellular-to-In Vivo Gap

Perhaps the most important moderating finding in this literature comes from a 2024 study ^[12] that tested MB against a SARS-CoV-2-related pangolin coronavirus across different experimental settings. MB demonstrated strong extracellular virucidal activity in vitro — meaning it could destroy viral particles in solution outside of cells. However, the same study found no intracellular efficacy and no in vivo efficacy. This is a significant distinction: destroying a virus particle in a test tube before it contacts cells is a very different challenge from inhibiting viral replication once infection has begun inside a living organism with pharmacokinetic constraints.

This finding is a useful frame for interpreting the entire body of MB antiviral research. Many positive results in this area are extracellular: MB inactivates virus in solution, often with light activation. The translation of that activity to a therapeutic context — where MB must reach infected tissues at effective concentrations without causing harm — has not been demonstrated. In vitro antimicrobial and antiviral studies are a necessary first step, but they are not clinical evidence.

A Note on the Evidence

The research summarized here is largely in vitro; results from laboratory studies do not establish clinical efficacy or safety for antimicrobial or antiviral applications in humans, and at least one study demonstrated that strong extracellular in vitro activity did not translate to in vivo efficacy [PMID 39599511]. Methylene blue carries serious risks — including serotonin syndrome risk with serotonergic medications, absolute contraindication in G6PD deficiency, and a paradoxical risk of methemoglobinemia at doses above approximately 4 mg/kg — and only USP pharmaceutical-grade product is appropriate for any human use; consult a qualified physician before considering any therapeutic application.

Frequently Asked Questions

How does methylene blue kill bacteria?

When activated by light, MB absorbs photons and transfers energy to molecular oxygen, generating singlet oxygen and other reactive oxygen species that damage bacterial membranes, proteins, and nucleic acids. This is the mechanism behind antimicrobial photodynamic therapy. Research has found this activity against biofilm-forming pathogens including A. baumannii and S. mutans [PMID 32289462, PMID 32407890], though outcomes depend heavily on light dose, MB concentration, and delivery to the target.

Does methylene blue have antimicrobial effects without light?

The primary mechanism studied in the papers cited here is light-dependent (photodynamic). Some proposed antiviral mechanisms — such as MB acting as a nonspecific protein-protein interaction inhibitor ^[8] or binding to the spike-ACE2 interface ^[6] — do not require light activation. However, light-independent antimicrobial activity is less well-characterized, and the photodynamic mechanism is the more consistently studied pathway.

Has methylene blue been tested against SARS-CoV-2?

Yes, in laboratory settings. A 2021 study demonstrated in vitro photodynamic inactivation of SARS-CoV-2 using MB ^[5], and computational and binding studies have explored how MB might interfere with spike protein interactions [PMID 33519460, PMID 37958892]. However, a 2024 study found strong extracellular virucidal activity but no intracellular or in vivo efficacy against a related coronavirus ^[12], highlighting that in vitro results do not translate automatically to biological or clinical settings.

Why are biofilms a special challenge for photodynamic therapy?

Biofilms are structured communities of bacteria embedded in a self-produced matrix that physically limits photosensitizer penetration and can reduce effective MB concentration at the bacterial surface. Research has addressed this through combination strategies: adding potassium iodide to amplify reactive species production ^[7] or blocking efflux pumps that expel MB from bacterial cells ^[1]. Even with these strategies, moving from laboratory biofilm models to clinical infection is complex.

Could methylene blue be used as an antiviral therapy in humans?

No antiviral clinical efficacy for MB has been established based on the evidence reviewed here. The studies are primarily in vitro, and at least one found no in vivo antiviral activity ^[12]. The concentrations required for antiviral effects in laboratory settings may not be achievable safely in humans. MB carries serious risks including serotonin syndrome when combined with serotonergic drugs and hemolytic anemia in individuals with G6PD deficiency. Any consideration of MB for therapeutic use requires physician guidance.

What is the significance of combining MB with potassium iodide in aPDT?

Potassium iodide acts as a potentiator: when singlet oxygen generated by light-activated MB reacts with iodide ions, it produces secondary reactive species including iodine radicals and hypoiodous acid, broadening the oxidative attack on the target. A 2022 study found this combination enhanced inactivation of S. mutans biofilm under red laser illumination compared with MB alone ^[7]. This suggests that additive chemistry can partly compensate for limitations in photosensitizer delivery, though the combination has not been evaluated clinically.

References

1. Kishen A et al. Efflux pump inhibitor potentiates antimicrobial photodynamic inactivation of Enterococcus faecalis biofilm. Photochemistry and photobiology (2010). PMID 20860692
2. Parasuraman P et al. Synthesis and antimicrobial photodynamic effect of methylene blue conjugated carbon nanotubes on E. coli and S. aureus. Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology (2019). PMID 30601523
3. Anane YA et al. In vitro antimicrobial photodynamic inactivation of multidrug-resistant Acinetobacter baumannii biofilm using Protoporphyrin IX and Methylene blue. Photodiagnosis and photodynamic therapy (2020). PMID 32289462
4. Nie M et al. Photodynamic inactivation mediated by methylene blue or chlorin e6 against Streptococcus mutans biofilm. Photodiagnosis and photodynamic therapy (2020). PMID 32407890
5. Svyatchenko VA et al. Antiviral photodynamic therapy: Inactivation and inhibition of SARS-CoV-2 in vitro using methylene blue and Radachlorin. Photodiagnosis and photodynamic therapy (2021). PMID 33249118
6. Bojadzic D et al. Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19. Frontiers in pharmacology (2020). PMID 33519460
7. Benine-Warlet J et al. Potassium iodide enhances inactivation of Streptococcus mutans biofilm in antimicrobial photodynamic therapy with red laser. Photodiagnosis and photodynamic therapy (2022). PMID 34775066
8. Chuang ST et al. Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19. Pharmaceuticals (Basel, Switzerland) (2022). PMID 35631447
9. Ribaudo G et al. Combining computational and experimental evidence on the activity of antimalarial drugs on papain-like protease of SARS-CoV-2: A repurposing study. Chemical biology & drug design (2023). PMID 36453012
10. Meerovich GA et al. Photodynamic inactivation of bacteria: Why it is not enough to excite a photosensitizer. Photodiagnosis and photodynamic therapy (2023). PMID 37863377
11. Kovalenko I et al. Interaction of Methylene Blue with Severe Acute Respiratory Syndrome Coronavirus 2 Envelope Revealed by Molecular Modeling. International journal of molecular sciences (2023). PMID 37958892
12. Wei L et al. Methylene Blue Has Strong Extracellular Virucidal Activity Against a SARS-CoV-2-Related Pangolin Coronavirus with No Intracellular or In Vivo Efficacy. Pathogens (Basel, Switzerland) (2024). PMID 39599511

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.